Patents by Inventor Christopher Umbricht

Christopher Umbricht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PSMA-binding agents and uses thereof
    Patent number: 11629201
    Abstract: The present invention provides novel compounds that are useful as radiopharmaceuticals, imaging agents and for treatment of cancer.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 18, 2023
    Assignees: ITM Isotope Technologies Munich SE, Paul Scherrer Institut
    Inventors: Martina Benesova, Cristina Müller, Christoph Umbricht, Roger Schibli, Konstantin Zhernosekov
  • NOVEL TUMOR ANTIGEN BINDING AGENTS AND USES THEREOF
    Publication number: 20220024882
    Abstract: The present invention provides compounds according to General Formula (1)(i) or (1)(ii): wherein A is a diagnostic or therapeutic agent comprising a binding site for a tumor antigen, and the spacer comprises at least one C—N bond.
    Type: Application
    Filed: November 28, 2019
    Publication date: January 27, 2022
    Inventors: Martina Benesova, Cristina Müller, Christoph Umbricht, Roger Schibli, Konstantin Zhernosekov, Luisa Maria Deberle
  • NOVEL PSMA-BINDING AGENTS AND USES THEREOF
    Publication number: 20210009715
    Abstract: The present invention provides novel compounds that are useful as radiopharmaceuticals, imaging agents and for treatment of cancer.
    Type: Application
    Filed: May 24, 2018
    Publication date: January 14, 2021
    Inventors: Martina Benesova, Cristina Müller, Christoph Umbricht, Roger Schibli, Konstantin Zhernosekov
  • Alternative splice variant patterns of human telomerase reverse transcriptase (hTERT) in thyroid tumors to distinguish benign from malignant
    Patent number: 10774389
    Abstract: This invention relates, e.g., to a method for determining if a thyroid tumor in a subject is malignant, comprising determining in a sample from the subject the amount of TERT (telomerase reverse transcriptase) mRNA which lacks the ? sequence and the amount of TERT mRNA in the sample which comprises the ? sequence, wherein a preponderance (e.g., at least about 55%) of TERT mRNA in the sample which comprises the ? sequence indicates that the tumor is malignant, and wherein a preponderance of TERT mRNA which lacks the ? sequence indicates that the tumor is not malignant.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: September 15, 2020
    Assignee: The Johns Hopkins University
    Inventors: Martha Allen Zeiger, Jeanne Kowalski, Christopher Umbricht, Yongchun Wang
  • ALTERNATIVE SPLICE VARIANT PATTERNS OF HUMAN TELOMERASE REVERSE TRANSCRIPTASE (hTERT) IN THYROID TUMORS TO DISTINGUISH BENIGN FROM MALIGNANT
    Publication number: 20180216192
    Abstract: This invention relates, e.g., to a method for determining if a thyroid tumor in a subject is malignant, comprising determining in a sample from the subject the amount of TERT (telomerase reverse transcriptase) mRNA which lacks the ? sequence and the amount of TERT mRNA in the sample which comprises the ? sequence, wherein a preponderance (e.g., at least about 55%) of TERT mRNA in the sample which comprises the ? sequence indicates that the tumor is malignant, and wherein a preponderance of TERT mRNA which lacks the ? sequence indicates that the tumor is not malignant.
    Type: Application
    Filed: September 29, 2017
    Publication date: August 2, 2018
    Inventors: Martha Allen Zeiger, Jeanne Kowalski, Christopher Umbricht, Yongchun Wang
  • ALTERNATIVE SPLICE VARIANT PATTERNS OF HUMAN TELOMERASE REVERSE TRANSCRIPTASE (hTERT) IN THYROID TUMORS TO DISTINGUISH BENIGN FROM MALIGNANT
    Publication number: 20160326592
    Abstract: This invention relates, e.g., to a method for determining if a thyroid tumor in a subject is malignant, comprising determining in a sample from the subject the amount of TERT (telomerase reverse transcriptase) mRNA which lacks the ? sequence and the amount of TERT mRNA in the sample which comprises the ? sequence, wherein a preponderance (e.g., at least about 55%) of TERT mRNA in the sample which comprises the ? sequence indicates that the tumor is malignant, and wherein a preponderance of TERT mRNA which lacks the ? sequence indicates that the tumor is not malignant.
    Type: Application
    Filed: December 10, 2015
    Publication date: November 10, 2016
    Inventors: Martha Allen Zeiger, Jeanne Kowalski, Christopher Umbricht, Yongchun Wang
  • Alternative splice variant patterns of human telomerase reverse transcriptase (hTERT) in thyroid tumors to distinguish benign from malignant
    Patent number: 9222136
    Abstract: This invention relates, e.g., to a method for determining if a thyroid tumor in a subject is malignant, comprising determining in a sample from the subject the amount of TERT (telomerase reverse transcriptase) mRNA which lacks the ? sequence and the amount of TERT mRNA in the sample which comprises the ? sequence, wherein a preponderance (e.g., at least about 55%) of TERT mRNA in the sample which comprises the ? sequence indicates that the tumor is malignant, and wherein a preponderance of TERT mRNA which lacks the ? sequence indicates that the tumor is not malignant.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: December 29, 2015
    Assignee: The Johns Hopkins University
    Inventors: Martha Allen Zeiger, Jeanne Kowalski, Christopher Umbricht, Yongchun Wang
  • METHOD FOR DIAGNOSING THE STAGE OF A THYROID TUMOR
    Publication number: 20110177971
    Abstract: The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer.
    Type: Application
    Filed: February 10, 2011
    Publication date: July 21, 2011
    Inventors: Steven K. Libutti, Chiara Mazzanti, Martha Zeiger, Christopher Umbricht
  • Diagnostic tool for diagnosing benign versus malignant thyroid lesions
    Patent number: 7901881
    Abstract: The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer.
    Type: Grant
    Filed: April 11, 2005
    Date of Patent: March 8, 2011
    Assignees: The United States of America as represented by the Department of Health and Human Services, The John Hopkins University
    Inventors: Steven K. Libutti, Chiara Mazzanti, Martha Zeiger, Christopher Umbricht
  • ALTERNATIVE SPLICE VARIANT PATTERNS OF HUMAN TELOMERASE REVERSE TRANSCRIPTASE (hTERT) IN THYROID TUMORS TO DISTINGUISH BENIGN FROM MALIGNANT
    Publication number: 20100260670
    Abstract: This invention relates, e.g., to a method for determining if a thyroid tumor in a subject is malignant, comprising determining in a sample from the subject the amount of TERT (telomerase reverse transcriptase) mRNA which lacks the ? sequence and the amount of TERT mRNA in the sample which comprises the ? sequence, wherein a preponderance (e.g., at least about 55%) of TERT mRNA in the sample which comprises the ? sequence indicates that the tumor is malignant, and wherein a preponderance of TERT mRNA which lacks the ? sequence indicates that the tumor is not malignant.
    Type: Application
    Filed: December 5, 2008
    Publication date: October 14, 2010
    Applicant: The Johns Hopkins University
    Inventors: Martha Allen Zeiger, Jeanne Kowalski, Christopher Umbricht, Yongchun Wang
  • Diagnostic Tool For Diagnosing Benign Versus Malignant Thyroid Lesions
    Publication number: 20080145841
    Abstract: The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer.
    Type: Application
    Filed: April 11, 2005
    Publication date: June 19, 2008
    Inventors: Steven K. Libutti, Chiara Mazzanti, Martha Zeiger, Christopher Umbricht